

Fact sheet

# A STRAIGHTFORWARD WAY TO GET REAL-WORLD DATA


*More innovative ways to think about RWD*

Real-world data (RWD) is anonymous patient-level data that is transforming how life science companies make decisions. These exponentially expanding datasets can provide unparalleled insights for scientific and commercial needs. But they vary greatly in quality and applicability. IQVIA™ is here to help you get the most from your RWD investments.

## A NEW WAY TO THINK ABOUT RWD: THE “T”

### T-SHAPED NETWORKS OFFER BOTH BREADTH AND DEPTH

- RWD sources spanning broad, near population-level cohorts provide important overviews of patients, diseases, and treatments
- Clinically rich, deep data for a discrete population of patients provides more detailed information to answer more complex clinical and market questions



# IQVIA RWD PORTFOLIO

## UNRIVALED GLOBAL SOURCE OF RWD

IQVIA takes a credible, user-friendly approach to bring you the right patient-level data, complemented by the technology, analytical, and medical, scientific & safety expertise to generate and interpret the RWE you need.



### MOST DATA

**10 data types** with modifications to methodology as required, determination of 'best use' alone or combined with other data – and ability to identify new data types as well.



### DISEASE AND THERAPY AREA DEPTH

Coverage of **nearly every disease**, including **very rare** conditions and supplement as needed, with extra investments already made in oncology and diabetes.



### MOST GLOBAL COVERAGE

Anonymous patient-level data on **500m+ patients** across **20+ countries** with access to our network of data providers in **50+ markets**.

## LARGEST VARIETY OF GLOBAL RWD ASSETS

With EMR data available in 9 countries, LRx data in 15 countries across 4 continents, and oncology survey data from more than 200,000 cases per year from more than 2,000 physicians, covering more than 25 tumor types, IQVIA is uniquely positioned to run multi-country RWD studies.

#### ELECTRONIC MEDICAL RECORDS (EMR)

Australia, Belgium, Canada, France, Germany, Italy, Spain, UK, USA

#### ADJUDICATED CLAIMS

Australia  
Canada  
UAE (Dubai)  
USA  
Japan

#### MEDICAL CLAIMS

USA, Brazil

#### HOSPITAL

Belgium, Portugal, Spain, Poland, UK, USA

#### LAB RESULTS/CONSUMER/ BEHAVIORAL

USA

#### LONGITUDINAL PRESCRIPTIONS (LRX)

Australia, Belgium, Canada, Finland, France, Germany, Hungary, Italy, Japan, Netherlands, Poland, Switzerland, UK, USA and Sweden

#### IQVIA RWD THERAPY AREA ASSETS

#### ONCOLOGY INTEGRATED EMR

USA

#### ONCOLOGY CROSS-SECTIONAL SURVEY

EU5 + China, South Korea, Japan, Mexico and Saudi Arabia

#### MULTIPLE THERAPEUTIC AREAS CROSS-SECTIONAL SURVEY

Italy, UK

#### HOSPITAL CLAIMS/DISCHARGE

Japan, UK

#### DATABASE NETWORK

Netherlands

#### ELECTRONIC MEDICAL RECORDS (EMR)

UK

#### REGISTRIES

Nordic Registry (Denmark, Finland, Iceland, Norway, Sweden)

#### CLAIMS

France, Germany

#### ONCOLOGY EMR

Germany

#### OPHTHALMOLOGY EMR

UK

#### GENOMIC ALTERATION DATA

USA, UK

*These are a few examples of IQVIA as licensed operator or collaboration partner*

# SOURCING AND LINKING EXPERTISE TO BUILD THE RIGHT RWD FOR YOUR NEEDS

## STRATEGIC DATA SOURCING


- Enhancing IQVIA RWD to generate complete patient views through custom sourcing support (e.g. eCRF, ePRO, NLP) and rapid custom sourcing to extract data and create custom datasets
- Identify and access new data sources addressing specific research needs, also in niche markets

### RWD CATALOGUE

Our expanding RWD Catalogue of 3,000+ sources globally spanning key therapy areas ensures we help clients access the best data for their research requirements

- Broad range of data sources including registries, claims, audits, EMR, clinical databases, biobanks and observational studies
- Switches focus from identifying data sources to assessing them

#### Current therapy area profile of the RWD catalogue



- Oncology
- Cardiovascular
- Endocrine, nutritional and metabolic
- Musculoskeletal and connective tissue
- Neurology
- Respiratory
- Multiple Therapy Areas
- Others

## DATA LINKAGE

- Understanding the full patient pathway through integrating datasets at the record level (eg, IQVIA RWD integrated offerings in the USA, Pygargus methodology in Scandinavia)

### CASE STUDIES USING IQVIA RWD

#### Increasing efficiency of RCT site selection with IQVIA RWD LRx

Used IQVIA RWD LRx data to assess number of RCT sites to recruit and inform target patient recruitment plan



#### Informing global forecasts with IQVIA RWD EMR

Used IQVIA RWD EMR to improve the accuracy of future volume to deliver a global forecast based on actual patient adherence



#### Finding undiagnosed rare disease patients using IQVIA RWD and predictive analytics

Built predictive models using IQVIA RWD LRx, Claims and de-identified patient support program data to find HCPs managing undiagnosed patients with a rare disease and promote targeted



#### Combining IQVIA RWD LRx with survey data to evaluate drug utilization

Analyzed IQVIA RWD LRx with physician survey data annually following product launch to evaluate drug utilization and monitor off-label use



## CREATING NEW DATA WHEN IT IS NOT ALREADY AVAILABLE

### REGISTRIES AND PROSPECTIVE RESEARCH


Our thousands of HEOR and advanced analytics experts and informatics specialists can help clients set up and support traditional types of data collection needs to support research that is not served with existing secondary data sources.

- Data is linked at a patient level across all relevant datasets, creating a holistic data journey for each individual patient within the study
- Enriched RWD studies allow for investigators to take advantage of the benefits of both methods of research while minimizing the trade-offs

### ENRICHED RWD STUDIES

Enriched RWD research studies enhance an existing EMR backbone with patient-level data from other sources such as claims, or de novo data collection such as a CRF.

Figure 1: Enriched RWD studies use multi-source data to provide a comprehensive view of the patient



Source: IQVIA analysis